Hiroyuki Takama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hiroyuki Takama has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Masashi Akiyama
Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Japan
10 shared publications - Daisuke Watanabe
Department of Dermatology Aichi Medical University Aichi Japan
9 shared publications Masashi Akiyama
Department of Dermatology, Aichi Medical University, Nagakute, Japan
8 shared publicationsDaisuke Watanabe
Department of Dermatology Aichi Medical University School of Medicine Nagakute Japan
6 shared publicationsYuichiro Ohshima
Department of Dermatology Aichi Medical University Aichi Japan
6 shared publicationsSumiko Makita
Department of Dermatology, Gifu Prefectural Tajimi Hospital, Gifu, Japan
4 shared publications
Latest Publications
- 25 February 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (5) , E219-E220
A case of adolescent striae distensae accompanied by ileitis
- 25 February 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (5) , E219-E220
A case of adolescent striae distensae accompanied by ileitis
- Open Access
- 17 January 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (5) , 570-578
Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study
Background: Recent case reports have shown the efficacy of apremilast for the treatment of palmoplantar pustulosis (PPP). However, no study has statistically analyzed the clinical efficacy of oral apremilast in patients with PPP.Objectives: To evaluate the effectiveness of apremilast, a phosphodiesterase 4 inhibitor, for PPP.Materials and Methods: Among 13 patients who were diagnosed with PPP, 10 patients with PPP with either palmoplantar pustules (>1 mm diameter) or sternoclavicular joint pain were retrospectively analyzed.Results: Palmoplantar Pustulosis Area and Severity Index (mean ± SD: baseline, 13.4 ± 9.5 vs. after treatment, 5.1 ± 5.6; P = 0.013) and the number of pustules measuring > 1 mm in diameter (3.9 ± 3.9 vs. 1.3 ± 1.9; P = 0.029) significantly improved in 2 (±1) weeks. Moreover, the Dermatology Life Quality Index (9.7 ± 7.0 vs. 3.3 ± 3.6; P = 0.009) and palmoplantar itching (visual analog scale [VAS] score) (5.6 ± 3.5 vs. 2.1 ± 2.2; P = 0.026) significantly improved in 2 weeks, whereas VAS scores of palmoplantar pain (4.8 ± 4.4 vs. 1.1 ± 2.4; P = 0.081) and sternoclavicular joint pain (3.2 ± 3.8 vs. 2.0 ± 2.6; P = 0.194) did not significantly improve. Diarrhea was observed in 60.0% of our patients.Conclusion: Our study demonstrated that apremilast can effectively treat cutaneous manifestations and arthralgia in Japanese patients with PPP who had apparent pustules and/or clavicular‐sternocostal arthralgia. Owing to the retrospective design of the study and a small sample size, placebo‐controlled clinical trials with a larger number of patients are warranted to confirm the efficacy of apremilast for treatment of PPP.
- 17 January 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (5) , 570-578
Open AccessImmediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study
Background: Recent case reports have shown the efficacy of apremilast for the treatment of palmoplantar pustulosis (PPP). However, no study has statistically analyzed the clinical efficacy of oral apremilast in patients with PPP.Objectives: To evaluate the effectiveness of apremilast, a phosphodiesterase 4 inhibitor, for PPP.Materials and Methods: Among 13 patients who were diagnosed with PPP, 10 patients with PPP with either palmoplantar pustules (>1 mm diameter) or sternoclavicular joint pain were retrospectively analyzed.Results: Palmoplantar Pustulosis Area and Severity Index (mean ± SD: baseline, 13.4 ± 9.5 vs. after treatment, 5.1 ± 5.6; P = 0.013) and the number of pustules measuring > 1 mm in diameter (3.9 ± 3.9 vs. 1.3 ± 1.9; P = 0.029) significantly improved in 2 (±1) weeks. Moreover, the Dermatology Life Quality Index (9.7 ± 7.0 vs. 3.3 ± 3.6; P = 0.009) and palmoplantar itching (visual analog scale [VAS] score) (5.6 ± 3.5 vs. 2.1 ± 2.2; P = 0.026) significantly improved in 2 weeks, whereas VAS scores of palmoplantar pain (4.8 ± 4.4 vs. 1.1 ± 2.4; P = 0.081) and sternoclavicular joint pain (3.2 ± 3.8 vs. 2.0 ± 2.6; P = 0.194) did not significantly improve. Diarrhea was observed in 60.0% of our patients.Conclusion: Our study demonstrated that apremilast can effectively treat cutaneous manifestations and arthralgia in Japanese patients with PPP who had apparent pustules and/or clavicular‐sternocostal arthralgia. Owing to the retrospective design of the study and a small sample size, placebo‐controlled clinical trials with a larger number of patients are warranted to confirm the efficacy of apremilast for treatment of PPP.
- Open Access
- 15 June 2020
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (13) , adv00182
Annular Sarcoidosis with Geographic Appearance in a Patient with Systemic Sarcoidosis
Is missing (Short communication)...
- 15 June 2020
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (13) , adv00182
Open AccessAnnular Sarcoidosis with Geographic Appearance in a Patient with Systemic Sarcoidosis
Is missing (Short communication)...
- 18 March 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (5) , E211-E213
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel
- 18 March 2020
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (5) , E211-E213
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel
- 3 February 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (2) , 890-903
SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation
The corneocyte lipid envelope, composed of covalently bound ceramides and fatty acids, is important to the integrity of the permeability barrier in the stratum corneum, and its absence is a prime structural defect in various skin diseases associated with defective skin barrier function. SDR9C7 encodes a short-chain dehydrogenase/reductase family 9C member 7 (SDR9C7) recently found mutated in ichthyosis. In a patient with SDR9C7 mutation and a mouse Sdr9c7-KO model, we show loss of covalent binding of epidermal ceramides to protein, a structural fault in the barrier. For reasons unresolved, protein binding requires lipoxygenase-catalyzed transformations of linoleic acid (18:2) esterified in ω-O-acylceramides. In Sdr9c7–/– epidermis, quantitative liquid chromatography–mass spectometry (LC-MS) assays revealed almost complete loss of a species of ω-O-acylceramide esterified with linoleate-9,10-trans-epoxy-11E-13-ketone; other acylceramides related to the lipoxygenase pathway were in higher abundance. Recombinant SDR9C7 catalyzed NAD+-dependent dehydrogenation of linoleate 9,10-trans-epoxy-11E-13-alcohol to the corresponding 13-ketone, while ichthyosis mutants were inactive. We propose, therefore, that the critical requirement for lipoxygenases and SDR9C7 is in producing acylceramide containing the 9,10-epoxy-11E-13-ketone, a reactive moiety known for its nonenzymatic coupling to protein. This suggests a mechanism for coupling of ceramide to protein and provides important insights into skin barrier formation and pathogenesis.
- 3 February 2020
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (2) , 890-903
SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation
The corneocyte lipid envelope, composed of covalently bound ceramides and fatty acids, is important to the integrity of the permeability barrier in the stratum corneum, and its absence is a prime structural defect in various skin diseases associated with defective skin barrier function. SDR9C7 encodes a short-chain dehydrogenase/reductase family 9C member 7 (SDR9C7) recently found mutated in ichthyosis. In a patient with SDR9C7 mutation and a mouse Sdr9c7-KO model, we show loss of covalent binding of epidermal ceramides to protein, a structural fault in the barrier. For reasons unresolved, protein binding requires lipoxygenase-catalyzed transformations of linoleic acid (18:2) esterified in ω-O-acylceramides. In Sdr9c7–/– epidermis, quantitative liquid chromatography–mass spectometry (LC-MS) assays revealed almost complete loss of a species of ω-O-acylceramide esterified with linoleate-9,10-trans-epoxy-11E-13-ketone; other acylceramides related to the lipoxygenase pathway were in higher abundance. Recombinant SDR9C7 catalyzed NAD+-dependent dehydrogenation of linoleate 9,10-trans-epoxy-11E-13-alcohol to the corresponding 13-ketone, while ichthyosis mutants were inactive. We propose, therefore, that the critical requirement for lipoxygenases and SDR9C7 is in producing acylceramide containing the 9,10-epoxy-11E-13-ketone, a reactive moiety known for its nonenzymatic coupling to protein. This suggests a mechanism for coupling of ceramide to protein and provides important insights into skin barrier formation and pathogenesis.
- 1 January 2020
- Published by Elsevier in Journal of Dermatological Science
- Vol. 97 (1) , 50-56
Reduced stratum corneum acylceramides in autosomal recessive congenital ichthyosis with a NIPAL4 mutation
- 1 January 2020
- Published by Elsevier in Journal of Dermatological Science
- Vol. 97 (1) , 50-56
Reduced stratum corneum acylceramides in autosomal recessive congenital ichthyosis with a NIPAL4 mutation
- 7 November 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (1) , E6-E7
Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report
- 7 November 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (1) , E6-E7
Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report
- 28 June 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (11) , E407-E408
Generalized eruptive histiocytoma: Pediatric case report and review of the published work
- 28 June 2019
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (11) , E407-E408
Generalized eruptive histiocytoma: Pediatric case report and review of the published work
- Open Access
- 1 June 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (6) , 518-521
Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- 1 June 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (6) , 518-521
Open AccessPalmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Open Access
- 3 April 2019
- Published by Wiley in The FEBS Journal
- Vol. 286 (13) , 2536-2548
Studies on differentiation‐dependent expression and activity of distinct transglutaminases by specific substrate peptides using three‐dimensional reconstituted epidermis
During skin formation, particularly during differentiation of keratinocytes, unique post‐translational modifications play a role in forming a proteinaceous supermolecule called the cornified envelope (CE), which is necessary for barrier function. Transglutaminases (TGs) are essential enzymes involved in the cross‐linking of various keratinocyte structural proteins to complete CE formation. The TG family consists of eight isozymes, with two members, TG1 and TG3, located mainly in the epidermis. In an in vitro three‐dimensional (3D) culture system, reconstruction of the epidermis allows cornification of the terminally differentiated keratinocytes. In this study, using isozyme‐specific substrate peptides that enable detection of TG activity, we investigated the expression and the activation pattern of each isozyme during differentiation in this culture system. In the differentiating cells, the protein levels, enzymatic activities, as well as localization of TG1 and TG3 exhibited distinct patterns. Specific knockdown of these enzymes by siRNA revealed less cornification, suggesting that each TG contributes to the epidermal formation. In conclusion, we demonstrate the efficiency of the 3D system for studying differentiation‐dependent expression and activity of distinct TGs by specific substrate peptides.Enzyme: Transglutaminase, EC2.3.2.13.
- 3 April 2019
- Published by Wiley in The FEBS Journal
- Vol. 286 (13) , 2536-2548
Open AccessStudies on differentiation‐dependent expression and activity of distinct transglutaminases by specific substrate peptides using three‐dimensional reconstituted epidermis
During skin formation, particularly during differentiation of keratinocytes, unique post‐translational modifications play a role in forming a proteinaceous supermolecule called the cornified envelope (CE), which is necessary for barrier function. Transglutaminases (TGs) are essential enzymes involved in the cross‐linking of various keratinocyte structural proteins to complete CE formation. The TG family consists of eight isozymes, with two members, TG1 and TG3, located mainly in the epidermis. In an in vitro three‐dimensional (3D) culture system, reconstruction of the epidermis allows cornification of the terminally differentiated keratinocytes. In this study, using isozyme‐specific substrate peptides that enable detection of TG activity, we investigated the expression and the activation pattern of each isozyme during differentiation in this culture system. In the differentiating cells, the protein levels, enzymatic activities, as well as localization of TG1 and TG3 exhibited distinct patterns. Specific knockdown of these enzymes by siRNA revealed less cornification, suggesting that each TG contributes to the epidermal formation. In conclusion, we demonstrate the efficiency of the 3D system for studying differentiation‐dependent expression and activity of distinct TGs by specific substrate peptides.Enzyme: Transglutaminase, EC2.3.2.13.